This research was supported by an NIMH Mentored Research Scientist Development Award (MH073920).
TRANSDIAGNOSTIC VERSUS DIAGNOSIS-SPECIFIC CBT FOR ANXIETY DISORDERS: A PRELIMINARY RANDOMIZED CONTROLLED NONINFERIORITY TRIAL
Article first published online: 5 JUL 2012
© 2012 Wiley Periodicals, Inc.
Depression and Anxiety
Volume 29, Issue 10, pages 874–882, October 2012
How to Cite
Norton, P. J. and Barrera, T. L. (2012), TRANSDIAGNOSTIC VERSUS DIAGNOSIS-SPECIFIC CBT FOR ANXIETY DISORDERS: A PRELIMINARY RANDOMIZED CONTROLLED NONINFERIORITY TRIAL. Depress. Anxiety, 29: 874–882. doi: 10.1002/da.21974
- Issue published online: 1 OCT 2012
- Article first published online: 5 JUL 2012
- Manuscript Accepted: 3 JUN 2012
- Manuscript Revised: 16 APR 2012
- Manuscript Received: 17 FEB 2012
- NIMH Mentored Research Scientist Development. Grant Number: MH073920
- cognitive–behavioral therapy;
- group therapy
Transdiagnostic cognitive–behavioral treatments for anxiety disorders have been gaining increased attention and empirical study in recent years. Despite this, research on transdiagnostic anxiety treatments has, to date, relied on open trials, or comparisons to waitlist conditions, published benchmarks, or relaxation-based interventions.
The current study was a randomized clinical trial examining the efficacy of a 12-week transdiagnostic cognitive–behavioral group treatment in comparison to 12-week diagnosis-specific group Cognitive-Behavioral Therapy (CBT) protocols for panic disorder, social anxiety disorder, and generalized anxiety disorder.
Results from 46 treatment initiators suggested significant improvement during treatment, strong evidence for treatment equivalence across transdiagnostic and diagnosis-specific CBT conditions, and no differences in treatment credibility.
This study provides evidence supporting the efficacy of transdiagnostic CBT by comparison to current gold-standard diagnosis-specific CBT for social anxiety disorder, generalized anxiety disorder, and panic disorder. Transdiagnostic group CBT has the benefit of potentially easing dissemination and increasing access to evidence-based treatments for anxiety without sacrificing efficacy.